Kinase inhibitors
There are provided compounds of formula I, wherein X, Ak, s, A, R 1 and R 2 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
1. A pharmaceutical formulation comprising a pharmaceutically acceptable adjuvant, diluent or carrier and a compound having the structure of Formula Ia,
or pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein:
X represents halo;
Ak represents C 1-6 alkyl optionally substituted by one or more fluorine atoms;
R 1 and R 2 each independently represents H, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl, or heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, oxo, —NR 3 SO 2 R 4 , —N═S(O)(R 4 ) 2 , —S(O) m R 5 , —P(O)(R 4 ) 2 , —C(O)NR 5 R 6 , —S(O) 2 NR 5 R 6 , —(OCH 2 CH 2 ) 0-4 OR 5 , —(CH 2 ) 0-4 —NR 5 R 6 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, aryl, heteroaryl or heterocyclyl, which latter seven groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy, oxo and hydroxy;
or R 1 and R 2 , together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated and which heterocyclic group contains one N atom (the atom to which R 1 and R 2 are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally fused to a benzene or heteroaromatic ring, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, —C(O)OH, —NR 3 SO 2 R 4 , —S(O) m R 5 , —C(O)NR 5 R 6 , —(CH 2 ) 0-4 —NR 5 R 6 , —(OCH 2 CH 2 ) 0-4 OR 5 , C 1-4 alkyl, C 1-4 alkoxy, aryl, heteroaryl, and heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy, oxo and hydroxy;
R 3 represents H or C 1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and C 1-2 alkoxy;
R 4 represents C 1-4 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl or heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, C 1-4 alkyl, oxo, hydroxy and C 1-4 alkoxy;
R 5 and R 6 each independently represent H, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl, or heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, oxo, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, —S(O) p R 7 , —C(O)NR a R b and —(CH 2 ) 0-4 —NR a R b , or
[C(R 6b )(R 6c )CH 2 Z] 1-12 —CH 2 CH 2 —R 6a or —C(R 6b )(R 6c )—[C 1-5 alkylene]-R 6a ;
or R 5 and R 6 , together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated and which heterocyclic group contains one N atom (the atom to which R 5 and R 6 are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, —C(O)OH, —S(O) p R 7 , —C(O)NR a R b , —(CH 2 ) 0-4 —NR a R b , —(OCH 2 CH 2 ) 0-4 OR c , C 1-4 alkyl, C 1-4 alkoxy, aryl, heteroaryl and heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy, oxo and hydroxy;
Z represents, independently upon each occurrence, —O—, —C(O)N(R 8 )— or —N(R 8 )C(O)—;
R 6a represents —OR 7a , —S(O) p R 7 , —N(R 7b )R 7c or —C(O)OH;
R 6b , R 6c and R 8 independently represent H or methyl;
R a , R b and R c independently represent H or C 1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and —C(O)OH,
or R a and R b , together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom (the atom to which R a and R b are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 hydroxyalkyl;
R 7 represents C 1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and C 1-4 alkoxy;
R 7a to R 7c independently represent H or C 1-4 alkyl optionally substituted by one or more halo atoms or by —C(O)OH,
or R 7b and/or R 7c represents —[C a alkylene]-[C b alkylene]-OR 7d ,
or R 7b and R 7c together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom (the atom to which R 7b and R 7c are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 hydroxyalkyl;
a and b independently represent an integer selected from 1, 2 and 3, wherein the sum of a and b is 2, 3 or 4;
R 7d represents H or C 1-4 alkyl optionally substituted by one or more halo atoms: and
m and p represent, independently upon each occurrence, 0, 1 or 2.
2. The pharmaceutical composition of claim 1 , wherein X represents fluoro and/or Ak represents C 1-3 alkyl.
3. The pharmaceutical composition of claim 1 , wherein:
R 1 and R 2 independently represent H, heterocyclyl, C 1-2 alkyl or phenyl, which latter two groups are optionally substituted by one or more substituents selected from heterocyclyl, halo, cyano, —OR 5a and methyl, which latter group is optionally substituted by one or more halo atoms; and
R 5a represents H or C 1-2 alkyl.
4. The pharmaceutical composition of claim 1 , wherein:
R 1 and R 2 , together with the N-atom to which they are attached, form a 5- or 6-membered heterocyclic group that is fully saturated and which heterocyclic group contains one N atom (the atom to which R 1 and R 2 are attached) and, optionally, one or two further heteroatoms selected from O, S and N, and which heterocyclic group is optionally fused to a benzene ring, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, oxo, —S(O) 2 R 5b , C 1-3 alkyl, C 1-3 alkoxy and heterocyclyl; and
R 5b represents C 1-2 alkyl.
5. The pharmaceutical composition of claim 1 , wherein each heterocyclyl group independently represents a 5- or 6-membered heterocyclic ring that is fully saturated, which group contains one or two heteroatoms selected from N, O and S.
6. The pharmaceutical composition of claim 1 , wherein the compound is:
[1,4′-bipiperidin]-1′-yl(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone;
(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(indolin-1-yl)methanone;
1-ethyl-4-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)piperazine-2,3-dione;
2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5 (4H)-carboxamide;
2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-N-(2-(2-methoxyethoxy)ethyl)-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5 (4H)-carboxamide;
2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-N-(4-(methylsulfonyl)phenyl)-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5 (4H)-carboxamide;
N-(3,5-dimethylisoxazol-4-yl)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5 (4H)-carboxamide;
N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5 (4H)-carboxamide;
N-(benzo[c][1,2,5]thiadiazol-4-yl)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5(4H)-carboxamide; or
2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-N-phenyl-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5(4H)-carboxamide;
or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
7. The pharmaceutical composition of claim 1 , wherein the compound is (2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(morpholino)methanone, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
8. The pharmaceutical composition of claim 1 , wherein the compound is (2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(pyrrolidin-1-yl)methanone, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
9. The pharmaceutical composition of claim 1 , wherein the compound is 2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-N-methyl-N-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxamide, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
10. A pharmaceutical formulation comprising a pharmaceutically acceptable adjuvant, diluent or carrier and a compound having the structure of Formula Ib,
or pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein:
X represents halo;
Ak represents C 1-6 alkyl optionally substituted by one or more fluorine atoms;
R 1 and R 2 each independently represents H, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl, or heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, oxo, —NR 3 SO 2 R 4 , —N═S(O)(R 4 ) 2 , S(O) m R 5 , —P(O)(R 4 ) 2 , —C(O)NR 5 R 6 , —S(O) 2 NR 5 R 6 , —(OCH 2 CH 210 -4OR 5 , —(CH 2 ) 0-4 —NR 5 R 6 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, aryl, heteroaryl or heterocyclyl, which latter seven groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy, oxo and hydroxy;
or R 1 and R 2 , together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated and which heterocyclic group contains one N atom (the atom to which R 1 and R 2 are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally fused to a benzene or heteroaromatic ring, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, —C(O)OH, —NR 3 SO 2 R 4 , —S(O) m R 5 , —C(O)NR 5 R 6 , —(CH 2 ) 0-4 —NR 5 R 6 , —(OCH 2 CH 2 ) 0-4 OR 5 , C 1-4 alkyl, C 1-4 alkoxy, aryl, heteroaryl, and heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy, oxo and hydroxy;
R 3 represents H or C 1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and C 1-2 alkoxy;
R 4 represents C 1-4 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl or heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, C 1-4 alkyl, oxo, hydroxy and C 1-4 alkoxy;
R 5 and R 6 each independently represent H, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl, or heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, oxo, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, —S(O) p R 7 , —C(O)NR a R b and —(CH 2 ) 0-4 —NR a R b , or
[C(R 6b )(R 6c )CH 2 Z] 1-12 —CH 2 CH 2 —R 6a or —C(R 6b )(R 6c )—[C 1-5 alkylene]-R 6a ;
or R 5 and R 6 , together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated and which heterocyclic group contains one N atom (the atom to which R 5 and R 6 are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, —C(O)OH, —S(O) p R 7 , —C(O)NR a R b , —(CH 2 ) 0-4 —NR a R b , —(OCH 2 CH 2 ) 0-4 OR c , C 1-4 alkyl, C 1-4 alkoxy, aryl, heteroaryl and heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy, oxo and hydroxy;
Z represents, independently upon each occurrence, —O—, —C(O)N(R 8 )— or —N(R 8 )C(O)—;
R 6a represents —OR 7a , —S(O) p R 7 , —N(R 7b )R 7c or —C(O)OH;
R 6b , R 6c , and R 8 independently represent H or methyl;
R a , R b and R c independently represent H or C 1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and —C(O)OH,
or R a and R b , together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom (the atom to which R a and R b are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 hydroxyalkyl;
R 7 represents C 1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and C 1-4 alkoxy;
R 7a to R 7c independently represent H or C 1-4 alkyl optionally substituted by one or more halo atoms or by —C(O)OH,
or R 7b and/or R 7c represents —[C a alkylene]-[C b alkylene]-OR 7d ,
or R 7b and R 7c together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom (the atom to which R 7b and R 7c are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, —C(O)OH, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 hydroxyalkyl;
a and b independently represent an integer selected from 1, 2 and 3, wherein the sum of a and b is 2, 3 or 4;
R 7d represents H or C 1-4 alkyl optionally substituted by one or more halo atoms: and
m and p represent, independently upon each occurrence, 0, 1 or 2.
11. The pharmaceutical composition of claim 10 , wherein X represents fluoro and/or Ak represents C 1-3 alkyl.
12. The pharmaceutical composition of claim 10 , wherein:
R 1 and R 2 independently represent H, heterocyclyl, C 1-2 alkyl or phenyl, which latter two groups are optionally substituted by one or more substituents selected from heterocyclyl, halo, cyano, —OR 5 a and methyl, which latter group is optionally substituted by one or more halo atoms; and
R 5a represents H or C 1-2 alkyl.
13. The pharmaceutical composition of claim 10 , wherein:
R 1 and R 2 , together with the N-atom to which they are attached, form a 5- or 6-membered heterocyclic group that is fully saturated and which heterocyclic group contains one N atom (the atom to which R 1 and R 2 are attached) and, optionally, one or two further heteroatoms selected from O, S and N, and which heterocyclic group is optionally fused to a benzene ring, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, oxo, S(O) 2 R 5b , C 1-3 alkyl, C 1-3 alkoxy and heterocyclyl; and
R 5b represents C 1-2 alkyl.
14. The pharmaceutical composition of claim 10 , wherein each heterocyclyl group independently represents a 5- or 6-membered heterocyclic ring that is fully saturated, which group contains one or two heteroatoms selected from N, O and S.
15. The pharmaceutical composition of claim 1 , wherein the compound is:
5-ethyl-2-fluoro-4-(3-(5-((4-(methylsulfonyl)piperazin-1-yl)sulfonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol;
1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5 (4H)-yl)sulfonyl)-N-methylpiperidine-4-carboxamide;
5-ethyl-2-fluoro-4-(3-(5-((4-m ethylpiperazin-1-yl)sulfonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol; or
4-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5 (4H)-yl)sulfonyl)piperazine-1-carbaldehyde;
or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
16. The pharmaceutical composition of claim 10 , wherein the compound is N-(2-cyanoethyl)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-N-(2-methoxyethyl)-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5(4H)-sulfonamide, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
17. The pharmaceutical composition of claim 1 , wherein the compound is 2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridine-5(4H)-sulfonamide, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
18. The pharmaceutical composition of claim 1 , wherein the compound is 5-ethyl-2-fluoro-4-(3-(5-(pyrrolidin-1-ylsulfonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
19. The pharmaceutical composition of claim 1 , wherein the compound is 5-ethyl-2-fluoro-4-(3-(5-(morpholinosulfonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
20. The pharmaceutical composition of claim 1 , wherein the compound is 4-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)sulfonyl)thiomorpholine 1,1-dioxide, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
21. The pharmaceutical composition of claim 1 , wherein the compound is 5-ethyl-2-fluoro-4-(3-(5-((4-methoxypiperidin-1-yl)sulfonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.